In 2025, the National Medicines Regulatory Authority (NMRA) of Sri Lanka announced a pivotal change in its approach to medical device regulation, the introduction of the Reliance Pathway for the registration of new medical device applications. This move represents a significant step toward greater efficiency, transparency, and predictability in the country’s regulatory review process.
Under the new pathway, the NMRA may rely on the assessments and approval decisions made by recognized Reference National Regulatory Authorities (NRAs) when sufficient regulatory evidence is available. Reference authorities include globally trusted regulators such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), UK Medicines and Healthcare Products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Health Canada, among others.
In essence, the Reliance Pathway allows Sri Lanka’s NMRA to recognize and leverage work already done by established regulators, accelerating access to safe and effective medical devices without duplicating existing assessments.
For medical device manufacturers and importers, this development is more than a procedural change, it’s a meaningful opportunity to enter the Sri Lankan market faster, reduce administrative burden, and align with global harmonization trends that are reshaping regulatory affairs worldwide.
Why This Matters to Manufacturers and Importers
Across global regulatory environments, “reliance” and “recognition” pathways are becoming increasingly important tools for optimizing medical device approvals. These approaches enable regulators to depend on trusted external evaluations and decisions when appropriate, allowing them to focus their resources on areas of higher regulatory uncertainty or risk.
For manufacturers and importers, the advantages of Sri Lanka’s new pathway are clear:
- Streamlined approvals for devices that have already been vetted by reputable authorities such as the FDA, EMA, or TGA.
- Reduced duplication of work, since NMRA can base its evaluation on existing, validated data and assessments.
- Greater transparency and predictability throughout the review process, with clearer timelines and expectations.
- Faster market access, enabling companies to reach Sri Lankan patients and providers more efficiently.
This update also positions Sri Lanka as part of a growing global movement toward regulatory reliance, a trend that supports regulatory convergence, strengthens mutual trust between agencies, and promotes faster access to quality medical technologies in emerging markets.
For multinational manufacturers, it’s an opportunity to expand regional market access using existing approvals from Reference NRAs. For local importers and authorized representatives, it offers a faster, more predictable route to introduce innovative devices that meet international safety and performance standards.
Key Details from NMRA’s 2025 Announcement
According to the NMRA’s official communication, the Reliance Pathway applies to new medical device applications, not renewals, amendments, or variations of existing registrations.
Eligibility
To qualify for consideration under the Reliance Pathway:
- The device must already be approved by a recognized Reference NRA (e.g., FDA, EMA, MHRA, TGA, HSA, or Health Canada).
- Applicants can be manufacturers, importers, or authorized representatives legally responsible for placing the device on the Sri Lankan market.
- Sufficient regulatory evidence must be available to demonstrate conformity and safety.
Evaluation Process
When an eligible application is submitted, the NMRA will review the documentation and, where the evidence is complete and the Reference NRA’s assessment meets NMRA standards, the Authority may adopt or abridge its review process accordingly.
This approach allows the NMRA to concentrate its expertise on verifying administrative and contextual details rather than re-assessing the full technical dossier from the ground up.
NMRA Reliance Pathway Application Checklist
To help manufacturers and authorized representatives prepare for this new process, below is a practical checklist outlining the major eligibility criteria, documentation requirements, and submission steps associated with the NMRA’s Reliance Pathway.
1. Eligibility Confirmation
| Requirement | Verification (✓ / Notes) |
|---|---|
| Device is a new medical device application (not renewal or variation). | |
| The device has been approved by a recognized Reference NRA (FDA, EMA, MHRA, TGA, HSA, or Health Canada). | |
| Reference NRA registration certificate and decision letter are available. | |
| Product is manufactured or legally represented in a country with a recognized NRA. | |
| Sufficient regulatory evidence (e.g., assessment report, approval letter, labeling, IFU) is available. |
2. Application Dossier Components
| Document / Component | Included (✓ / Notes) |
|---|---|
| Completed NMRA Reliance Pathway application form. | |
| Proof of Reference NRA approval (certificate/decision letter). | |
| Device description, classification, and intended use. | |
| Evidence of conformity to relevant ISO standards (e.g., ISO 13485, ISO 14971). | |
| Device labeling (in English or Sinhala). | |
| Quality Management System (QMS) certificate. | |
| Letter of authorization for local agent or importer. | |
| Declaration of conformity. | |
| Business registration or manufacturing license. | |
| Post-market surveillance plan (if required). |
3. Submission and Review Process
- Confirm eligibility for the Reliance Pathway based on Reference NRA registration and available evidence.
- Compile all dossier components according to NMRA’s guidance.
- Submit the application via NMRA’s designated portal or physical submission channel, as directed.
- NMRA conducts an administrative screening to verify documentation and confirm Reference NRA credentials.
- Applicants respond to any NMRA queries or requests for clarification.
- Upon successful verification, NMRA issues the approval and registration certificate.
Applicants should keep in mind that the NMRA retains final decision-making authority, even when leveraging Reference NRA approvals.
Why This Represents a Broader Shift in Regulatory Strategy
Sri Lanka’s introduction of the Reliance Pathway aligns with a wider movement among regulatory authorities in Asia and beyond to strengthen collaboration and reduce redundancy in device evaluation. Regulators such as Singapore’s Health Sciences Authority (HSA), Malaysia’s MDA, and the African Medicines Regulatory Harmonization (AMRH) initiative have all implemented forms of reliance or recognition pathways.
These frameworks help accelerate patient access to quality-assured medical devices while maintaining regulatory rigor. By joining this trend, Sri Lanka is signaling its commitment to global best practices and regulatory modernization.
For manufacturers, this means that approvals obtained in highly regulated markets can now serve as a gateway to faster entry in Sri Lanka, provided the documentation and regulatory evidence meet NMRA’s expectations. This evolution also helps NMRA strengthen capacity by allowing its reviewers to focus on context-specific issues such as labeling, language requirements, and post-market surveillance, while leveraging trusted external assessments for core safety and performance data.
Preparing for Success Under the Reliance Pathway
Manufacturers planning to utilize Sri Lanka’s Reliance Pathway should start by auditing their existing documentation and ensuring alignment with NMRA’s expectations.
Key steps include:
- Identify eligible products already approved by one or more recognized NRAs.
- Verify completeness of all regulatory evidence, including decision letters, summaries of assessment, and quality certificates.
- Ensure accurate and up-to-date labeling that meets Sri Lankan language and format requirements.
- Establish local representation through an authorized importer or agent to manage communications with NMRA.
- Monitor updates to NMRA guidance, as the Reliance Pathway framework may evolve with implementation.
These steps will position applicants to take full advantage of the streamlined review process while maintaining compliance and readiness for potential NMRA requests.
Conclusion
The NMRA’s introduction of the Reliance Pathway for new medical device applications marks a major advancement in Sri Lanka’s regulatory landscape. By leveraging trusted international approvals, the Authority is creating a more efficient, transparent, and predictable process, one that benefits both regulators and industry stakeholders.
For manufacturers and importers, this pathway offers a faster route to market, reduced administrative effort, and greater regulatory certainty. It also signals Sri Lanka’s growing integration into the global framework of regulatory reliance and harmonization, a trend that supports patient access to safe, high-quality medical devices worldwide.
As this initiative takes shape, staying informed and prepared will be key. Manufacturers that align early with NMRA’s requirements can not only accelerate approvals but also strengthen their regional market strategy in South Asia.
To stay updated, visit the NMRA official announcements page and monitor future guidance related to the Reliance Pathway.
